(MedPage Today) — CHICAGO — Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in patients with PD-L1-positive…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115829
Author :
Publish date : 2025-05-31 12:00:00
Copyright for syndicated content belongs to the linked Source.
